Read all about the latests in HIV/Aids research and treatment protocols and also developments made into various specific components of managing this disease that is by itself also evolving.
HIV News: University of British Columbia researchers have concluded a new study of which the findings are set to change international treatment recommendations for individuals who are newly diagnosed with HIV, an update that could affect nearly two million people per year worldwide.
The research found that the antiviral dolutegravir is the optimal medication for first-line treatment for i...
HIV Drugs: According to researchers from the University of Washington-Seattle, the commonly used HIV drug that is to treat those infected and also individuals using it as a prophylaxis or in PrEP protocols can induce a type I/III interferon-associated signature and inflammation throughout the gut.
It should be noted that long term inflammation of any kind can lead to a variety of chronic ...
HIV News: Researchers from University of Michigan Health System have discovered that a class of antibiotics called pleicomacrolides allows the immune system to kill HIV infected cells by inhibiting the Nef proteins.
The research finds are published in the Journal of The Proceedings of the National Academy Of Sciences of The United States Of America (Concanamycin A counteracts HIV-1 Nef to...
HIV News: The trend for HIV drug research is now shifting towards drugs with long lasting effects without the need for HIV patients to adhere to stringent daily regimens and doses which can be quiet stressful at times.
Scientists from the University of Utah Health in collaboration with researchers from the National Institute of Allergy and Infectious Diseases (NIAID), Beth Israel Deacones...
HIV Drug News: Researchers at the George Washington University in a new study have discovered that Fingolimod, a US FDA-approved immunosuppressive drug used to treat multiple sclerosis flare-ups, may be used to effectively block HIV infection and reduce the latent virus reservoir.
The research findings were published in the journal: PLOS Pathogens. https://journals.plos.org/plospathogens/...
HIV Research: The significant impact and prevalence of heart disease and other critical comorbidities on an aging global population with human immunodeficiency virus (HIV) have emerged from a suite of articles in The Journal of Infectious Diseases that contains the first swath of important data from the world's largest study of cardiovascular disease (CVD) prevention in people with H...
Source: COVID-19 And HIV Jul 05, 2020 5 months ago
COVID-19 And HIV: Individuals with HIV who were hospitalized with COVID-19 did not have worse results than COVID-19 patients without HIV, according to new research by Icahn School of Medicine at Mount Sinai.
The research findings were published in the journal: Clinical Infectious Diseases https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa880/5864410?searchresult=1
Study...
HIV Drugs: The drug Rukobia (fostemsavir) has been approved by The U.S. FDA for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations.
Rukobia (Fostemsavir) is a new type of antiretroviral medication to be taken twice daily by mouth. It is a prodrug, whi...
Source: HIV and Lenacapavir Jul 02, 2020 5 months ago
HIV and Lenacapavir: Gilead scientists are reporting an early step toward an HIV drug that could potentially be taken only a couple of times per year.
A new study showed that a single injection of the experimental drug, called lenacapavir, was able to lower blood levels of HIV in a small group of patients. And it was capable of maintaining active levels in the blood for more than six...
HIV: Immunology researchers from the Yerkes National Primate Research Center and the Emory Vaccine Center (EVC) are first to show a new adjuvant, 3M-052, helps induce long-lasting immunity against HIV.
The research findings are published today in the journal: Science Immunology. https://immunology.sciencemag.org/content/5/48/eabb1025
Significantly, in this pre-clinical study&n...
HIV: Medical researchers from Rush University Medical Center, Temple University School of Medicine and the University Of Texas Medical Branch have found that astrocytes, a type of brain cell can harbor HIV and then spread the virus to immune cells that traffic them out of the brain and into other organs.
It was observed that HIV moved from the brain via this route even when the virus was ...
HIV Research: Medical researchers have known for a long time that despite the advancements in antiretroviral therapy, varying amounts HIV virus remains in infected individuals forever, hiding in small reservoirs of cells of the immune system. Should ever these individuals discontinue the antiretroviral therapy, the HIV virus almost always rebounds rapidly from the reservoirs, causing deadly sympto...
Source : Thailand Medical News Feb 19, 2020 9 months ago
Non-alcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD) and is characterized by liver inflammation and cell damage. It is a potentially dangerous condition that can progress to cirrhosis or liver cancer. Unfortunately, HIV patients tend to have a high prevalence of the disease.
A new study by McGill University, Canada has found that Vitamin E can ...
Source: Thailand Medical News Feb 01, 2020 10 months ago
Typically antiretroviral drugs are the gold standard for the treatment of HIV infection. They are highly effective in suppressing replication of the virus but require lifelong daily application and can be associated with side effects. Due to the high mutability of HIV and its capacity for rapid adaptation, combinations of antiretroviral agents are required to prevent the development of drug resist...
Source: Thailand Medical News Jan 23, 2020 10 months ago
More than 42 million people are infected with HIV worldwide, about 1.5 million people in the United States alone. Currently, people with HIV take antiretroviral therapy (ART), which can suppress HIV to undetectable levels in blood, but the virus persists throughout the body in latently infected resting CD4+ T cells. The immune system cannot recognize these cells and no current therapies can elimin...
Source: Thailand Medical News Jan 09, 2020 11 months ago
A research discovery by Florida State University College of Medicine researchers is expected to open the door for new and more potent treatment options for many of the more than 45 million people worldwide infected with the HIV virus and for others chronically ill with hepatitis B.
Professor Dr Zucai Suo of the FSU College of Medicine. Credit: Colin Hackley/FSU
Their study has established for t...
Source: Thailand Medical News Jan 07, 2020 11 months ago
New nonhuman primate research suggests for the first time that a single dose of an antibody-based treatment can prevent HIV transmission from mother to baby. The findings are being published in the journal Nature Communications.
The time or period when that single dose is given is key, however. The study found rhesus macaque newborns did not develop the monkey form of HIV, called SHIV, whe...
Source: Thailand Medical News Dec 18, 2019 12 months ago
Despite early antiretroviral therapy, or ART, has ensured less deadly outcomes for children living with and exposed to HIV, studies show the virus still may affect the brain. HIV may disrupt neurodevelopment, affecting how children learn, reason and function.
Dr Michael Boivin, professor and director of the Psychiatry Research Program in the Michigan State University College of Osteopathic Medi...
Source: Thailand Medical News Dec 12, 2019 12 months ago
A study of human cells and tissues by researchers at the National Institutes of Health and the University of Bologna, Italy has shown that Nano-sized vesicles released by certain bacteria that inhabit the vagina may protect against HIV infection.
Typically known as extracellular vesicles, these bubble-like particles are produced by many kinds of cells and are thought to transport molecules...
Source: Thailand Medical News Nov 30, 2019 1 year ago
For babies are born with HIV, starting treatment within hours to days is critical and important according to a new study led by researchers from Harvard. Unfortunately the norm in many countries is to wait for weeks or even months.
The study findings, from a small but unique study in Botswana, could influence care in Africa and other regions hit hard by the virus. They also might offer a ...
Source: Thailand Medical News Nov 25, 2019 1 year ago
Researchers at Scripps Research, California and the nonprofit vaccine research organization IAVI who are developing an experimental HIV vaccine has reached an important milestone by eliciting antibodies that can neutralize a wide variety of HIV strains.
The tests, in animal models,showed that these “broadly neutralizing” antibodies, or bnAbs, targeted at least two critical sites on ...
Source: Thailand Medical News Nov 21, 2019 1 year ago
Despite a few past research studies that links HIV with 'erosion" of the gut's intestinal linings, leading to inflammation and also the ‘leaky gut” syndrome, many HIV patients and even doctors are not aware of this.
In one past research in 2014, researchers at University of California, Davis had made some surprising discoveries about the body's initial response...
Source: Thailand Medical News Nov 15, 2019 1 year ago
In a study by researchers from Johns Hopkins University School of Medicine comparing medical information from portable EKG patch data from men living with HIV and also men without it, the researchers report they have found more variability of the electrical "reset" period between heartbeats known as the QT interval in men living with the virus, which may contribute to the increased...
Source: Thailand Medical News Nov 11, 2019 1 year ago
A new study demonstrates that women with HIV are more likely to enter the menopause transition at an average age of 48 years, 3 years younger than the general population. Study results are published online in Menopause, the journal of The North American Menopause Society (NAMS).
Typically, newly diagnosed HIV-positive patients who adhere to the latest therapy protocols are expected to...
Source: Thailand Medical News Nov 10, 2019 1 year ago
A group of medical and genomic researchers in Maryland from a company called American Gene Technologies announced that they have the answer for curing HIV/AIDS using gene therapy. The company hopes to initiate medical trials of a new gene therapy drug that it says can cure HIV.
American Gene Technologies (AGT), a Rockville-based medical research company, has submitted a Investigational New...
Source: Thailand Medical News Nov 07, 2019 1 year ago
Abbott announced today that a team of its scientists identified a new subtype of the human immunodeficiency virus (HIV), called HIV-1 Group M, subtype L.1 The findings, published today in the Journal of Acquired Immune Deficiency Syndromes (JAIDS), show the role next-generation genome sequencing is playing in helping researchers stay one step ahead of mutating viruses and avoiding n...
Source: Thailand Medical News Oct 26, 2019 1 year ago
Medical researchers from the US National Institutes of Health and the Massachusetts General Hospital (MGH) in Boston report that the injectable hormone tesamorelin (Egrifta) reduces liver fat and prevents liver fibrosis (scarring) in people living with HIV.
Dr Anthony S. Fauci,NIAID Director (NIAID is one of the entities under the NIH) commented in a phone interview with Thailand Medical ...
Source: Thailand Medical News Oct 24, 2019 1 year ago
From 2007 to 2018, there has been more than 37 studies that show that Selenium supplementation is good for HIV patients. Selenium supplementation has demonstrated the ability to reduce viral loads of the HIV virus while also preventing CD4 levels from declining and helping it achieve moderate gains.
Todate, there are been no known reactions or contraindications for those taking antiretrov...
Source: Thailand Medical News Oct 23, 2019 1 year ago
An new research study involving an international collaboration that included the University of Cape Town (UCT), Centre for the AIDS Program of Research in South Africa (CAPRISA) and the University of North Carolina at Chapel Hill (UNC) has revealed an unexpected finding that could lead to better therapies towards reducing the HIV reservoir, a major barrier to developing a cure for HIV. The reservo...
Source: Thailand Medical News Oct 05, 2019 1 year ago
The US FDA has approved second PrEXp (pre-exposure prophylaxis) drug, Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) to help prevent HIV infections. The drug is for in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. Descovy is not indicated...
Source: Thailand Medical News Sep 25, 2019 1 year ago
Thailand Medical News is pleased to present this simple guide with regards to essential micronutrients, health supplements and herbal products for people living with HIV. It is not mean for anyone to abstain from their prescribed antiretroviral therapies and before commencing any consumption any of these products, always consult your doctors first.
Micronutrients
All vitamins and minerals are ...
Source: Thailand Medical News Sep 24, 2019 1 year ago
CAR-T, a type of immunotherapy may have made its name as the cancer breakthrough of this century, but its roots dig far back to one of humanity’s other terrifying medical enemy: HIV. CAR-T is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then t...
Source: Thailand Medical News Sep 23, 2019 1 year ago
Longterm patients will ultimately face increased incidence of heart disease, COPD, Tuberculosis and bone fractures according to a new study. These are the areas that HIV patients need to take extra care off besides their antiretroviral regimens.
Academics from Anglia Ruskin University (ARU) in Cambridge and the Medical University of Vienna conducted the first ever large-scale review into th...
Source: Thailand Medical News Sep 21, 2019 1 year ago
For those on Antiretroviral therapy for prevention or treatment of HIV, whether on a single pill or combo regimen, it can be burdensome making sure the drugs are consumed without fail at the right times despite having a busy daily schedule. Those days might soon be over thanks to medical researchers across multiple departments at the University of North Carolina who collaborated on a seven-y...
Source: Thailand Medical News Sep 20, 2019 1 year ago
Results of a study that was conducted in South Africa using the RV144/Thai vaccine regimen that showed modest protection in an efficacy study conducted in Thailand, where clades B and E are prominent indicated significant cellular and antibody responses in study participants with clade C as the dominant circulating strain of HIV.
"Trial Responses Dispels The Notion That Each Strain or Clade...
Source: Thailand Medical News Aug 08, 2019 1 year ago
A new potential medication that works with an HIV-infected person's own body to further suppress the ever present but silent virus that available HIV treatments are unable to combat has been discovered by a team of medical scientist from University of Texas Medical Branch at Galveston.
In an exclusive interview with Thailand Medical News, lead author Assistant Professor Haito Hu comme...
Source: Thailand Medical News Jul 15, 2019 1 year ago
Findings from the recent START study involving 4684 adult HIV-positive patients from various countries showed that starting antiretroviral therapy (ART) has significant benefits and entails few risks for individuals with a low pre-treatment viral load. All the patients in the study had a CD4 cell count above 500 cells/mm3 and were randomised to start immediate ART or to defer therapy until th...
Source: Thailand Medical News Jun 22, 2019 1 year ago
New immunity cells known as CD11c+ dendritic cells have been identified by a team of researchers from The Westmead Institute For Medical Research in Sydney.These CD11c+ dendritic cells are extremely susceptible to the HIV virus and can transmit the virus to other cells especially the CD4 T Cells.
These CD11c+ dendritic cells are a type of dendritic cells that play a role in capturing any i...
Source: Thailand Medical News Jun 04, 2019 2 years ago
Most HIV patients have a 60% risk of developing a form of cancer during their life-span.
Cancers like Lymphoma, Lung Cancer, Anal Cancer, Cervical Cancer, Oral and oropharyngeal cancer ,liver cancer, skin cancer and also Kaposi's sarcoma are most prevalent among HIV patients.
At the recent ASCO presentation, study led by doctors at Fred Hutchinson Cancer Research Center showed that pati...
Source: La Jolla Institute for Immunology, California May 11, 2019 2 years ago
A new HIV vaccine delivery strategy appears to enhance the protective immune response in a preclinical model. Scientists at the La Jolla Institute for Immunology (LJI) have discovered that delivering an HIV vaccine in small doses over a series of days leads to a stronger immune response than when the same vaccine is given all at once.
A similar escalating dose method could be the best way...
Source: NIH/National Institute of Allergy and Infectious Diseases,US Apr 18, 2019 2 years ago
Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine. Results of the Phase 2, open-label study indicate the antibody, known as UB-42...
Source: The London School of Medicine (Blizard Institute) Apr 05, 2019 2 years ago
A recent research found that long-term cotrimoxazole treatment reduces mortality and morbidity in children with HIV by altering their gut microbiome and immune activation.
The finding supports current WHO guidelines, which recommend long-term cotrimoxazole treatment for all HIV-positive people living in areas where malaria and severe bacterial infections are common.
Previous studies have shown...
Source: Conference on Retroviruses and Opportunistic Infections (CROI 2019) ,Seattle. Mar 10, 2019 2 years ago
A combination of two long-acting injectable anti-HIV drugs taken once monthly had a very low rate of treatment failure and a favourable safety profile, according to results from two phase III trials presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle.
Dual injections of cabotegravir, an experimental integrase inhibitor, and the no...
Source: George Mason University Feb 15, 2019 2 years ago
George Mason University's Yuntao Wu is the lead scientist on a research team that has identified a measurable indicator that could prove instrumental in the fight against HIV.
The research focuses on cofilin, a key protein that regulates cells to mobilize and fight against infection.
In an HIV-infected patient, cofilin dysfunction is a key factor in helper T cell defects, according to the r...
Source: Simon Fraser University Feb 03, 2019 2 years ago
The immune system is the body's best defense in fighting diseases like HIV and cancer. Now, an international team of researchers is harnessing the immune system to reveal new clues that may help in efforts to produce an HIV vaccine.
SFU professor Mark Brockman and co-authors from the University of KwaZulu-Natal in South Africa have identified a connection between infection cont...
Source: Howard Hughes Medical Institute Jan 31, 2019 2 years ago
Researchers can now quickly and accurately count a hidden, inactive form of the human immunodeficiency virus (HIV) that lurks in patients' cells. This version of HIV embeds into cells' genomes and can persist despite otherwise successful therapies, thwarting attempts to cure the infection.
Using a new genetic technique developed by Howard Hughes Medical Institute Investigator Robert Sil...
Much of the research on HIV has focused on preventing infection but little is understood about how the body keeps the virus in check post-infection. A new study by Yale investigators reveals the role of a protein that serves to block HIV gene expression once it has entered human cells.
The research team, led by Manabu Taura, a postdoctoral fellow in the laboratory of immunobiologist ...
Source: Massachusetts General Hospital Jan 13, 2019 2 years ago
A study from a Massachusetts General Hospital (MGH) research team has identified the specific function of a protein found in HIV and related viruses that appears to slow down viral spread in the earliest stages of infection. But they also found that, after initially slowing down the spread of infection, that function may help the virus survive later on by evading the immune response. Their report ...
Source: Pasteur Institute Jan 01, 2019 2 years ago
Current HIV treatments need to be taken for life by those infected as antiretroviral therapy is unable to eliminate viral reservoirs lurking in immune cells. Institut Pasteur scientists have identified the characteristics of CD4 T lymphocytes that are preferentially infected by the virus – it is their metabolic (or energy-producing) activity1 that enables the virus to multiply. Thanks to met...
Source: Mary Ann Liebert, Inc Dec 13, 2018 2 years ago
A new study has shown that HIV-infected men had lower median bone mineral density (BMD) scores at the hip compared to HIV-uninfected men, and all men who received testosterone had significantly greater BMD scores at the lumbar spine. Further, in HIV-infected men with virologic suppression testosterone was significantly associated with a higher BMD score at the lumbar spine, as reported in AID...
Source: University Of Montreal Dec 01, 2018 2 years ago
Of the 50 million people around the world infected with HIV, less than one per cent have immune systems strong enough to suppress the virus for extended periods of time. These special immune systems are known as "elite controllers." But how do they actually fight HIV? Canadian scientists think they've found an important clue.
TRIM5 Alpha protein
Working in collaboration with a team...
Source: Johns Hopkins University Of Medicine Nov 28, 2018 2 years ago
Researchers at Johns Hopkins have identified two patients with HIV whose immune cells behave differently than others with the virus and actually appear to help control viral load even years after infection. Moreover, both patients carry large amounts of virus in infected cells, but show no viral load in blood tests. While based on small numbers, the data suggest that long-term viral remission migh...
Source: Public Library Of Science, US Nov 16, 2018 2 years ago
Mechanisms that govern HIV transcription and latency differ in the gut and blood, according to a study published November 15 in the open-access journal PLOS Pathogens by Steven Yukl of San Francisco Veterans Affairs Medical Center and the University of California, San Francisco, and colleagues. According to the authors, the findings could inform new therapies aimed at curing HIV.
HIV R...
Source: University of California Nov 01, 2018 2 years ago
Researchers are investigating other antiretrovirals, antibodies, injectables, implants, vaginal rings, vaginal films and other products
Oral pre-exposure prophylaxis (PrEP) based on tenofovir disoproxil fumarate /emtricitabine (Truvada)has set a high bar for prevention effectiveness, but a range of alternative PrEP products are in development, Raphael Landovitz of the University of...
The newest once-daily, all-in-one HIV combination pills can maintain undetectable viral load for two years and counting, according to a set of studies presented at ID Week 2018 this month in San Francisco.
Two phase 3 clinical trials showed that most people who took the bictegravir-based Biktarvy co-formulation or the doravirine-based Delstrigo pill for first-line t...
.jpg)
.jpg)
.jpg)
